Genomed (WAR:GEN) Other Stockholders Equity: zł10.59 Mil (As of Mar. 2026)


WAR:GEN Genomed SA WAR:GEN
75 GF Score
Price zł29.20
GF Value zł37.98
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Genomed Other Stockholders Equity?

Genomed WAR:GEN -1.35% 75 Other Stockholders Equity is zł10.59 Mil as of Mar. 2026. GuruFocus rates WAR:GEN with a GF Score™ of 75/100 and a GF Value™ of zł37.98 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Genomed's Other Stockholders Equity for the quarter that ended in Mar. 2026 was zł10.59 Mil.

Genomed's quarterly Other Stockholders Equity declined from Sep. 2025 (zł10.59 Mil) to Dec. 2025 (zł10.59 Mil) but then increased from Dec. 2025 (zł10.59 Mil) to Mar. 2026 (zł10.59 Mil).

Genomed's annual Other Stockholders Equity increased from Dec. 2023 (zł9.00 Mil) to Dec. 2024 (zł9.48 Mil) and increased from Dec. 2024 (zł9.48 Mil) to Dec. 2025 (zł10.59 Mil).

Genomed Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Genomed's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomed Other Stockholders Equity Chart

Genomed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.43 8.67 9.00 9.48 10.59

Genomed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.48 10.59 10.59 10.59 10.59
WAR:GEN
75GF Score
Genomed SA WAR:GEN
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomed Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of zł10.59 Mil mean?
Genomed (WAR:GEN) has a Other Stockholders Equity of zł10.59 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Genomed and its competitors.
Is Genomed's Other Stockholders Equity too high?
Genomed's current Other Stockholders Equity is zł10.59 Mil. Overall, Genomed has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomed's Other Stockholders Equity compare to TMO and DHR?
Genomed's Other Stockholders Equity of zł10.59 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Diagnostics & Research company?
A good Other Stockholders Equity depends on the Medical Diagnostics & Research industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Genomed and its competitors. Genomed's current Other Stockholders Equity is zł10.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomed stock overvalued right now?
Based on GuruFocus' analysis, Genomed (WAR:GEN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł37.98, compared to a current price of zł29.20 — trading 23.1% below its estimated fair value. The current Other Stockholders Equity is zł10.59 Mil. Genomed's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Genomed (WAR:GEN), the current Other Stockholders Equity is zł10.59 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomed (WAR:GEN) Overvalued in 2026?

Based on GuruFocus' analysis, Genomed stock appears to be undervalued. The current stock price of zł29.20 is trading 23.1% below its estimated GF Value™ of zł37.98. GuruFocus considers Genomed to be Modestly Undervalued.

Key valuation signals for WAR:GEN:

  • Other Stockholders Equity: zł10.59 Mil
  • GF Value™: zł37.98 vs. price of zł29.20 (23.1% below fair value)
  • GF Score™: 75/100 with 2 warning signs

No single metric tells the full story. See the WAR:GEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomed Business Description

Address Ulica Ponczowa 12, Warszawa, POL, 02-971
Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes.
75GF Score

Get the complete analysis for WAR:GEN

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł29.20
Price
zł37.98
GF Value